PMU56 IMPACT OF FDA APPROVAL OF NEW AGENTS ON THERAPEUTIC OPTIONS FOR GENETIC VARIANTS IN PEDIATRIC TUMORS

Abstract

Authors

H. Russell H. Smith F. Lin A. Roy S. Plon W. Parsons

Full Text Cite This Article
Back to Volume 23, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×